About Formosa Pharmaceuticals

Board of Directors

Dr. CY Cheng founded Formosa Laboratories, Inc. in 1996, and Formosa Pharmaceuticals in 2010. He received his Ph.D. degree in Medicinal Chemistry from University of California, San Francisco, and conducted postdoctoral research at MIT. He has over 35 years’ pharmaceutical industrial experience including at DuPont in Delaware (United States). Just prior to his industrial engagements, Dr. Cheng was also a Professor in the College of Pharmacy at National Taiwan University.
Dr. Hong-Jen Chang currently serves as Chairman and CEO of YFY Biotech Management Company. Prior to joining the YFY Group, Dr. Chang gained extensive experience in the health care sectors. During his 16-year service with the government, he held several key positions in the Taiwanese Ministry of Health and Welfare and served as President & CEO of Bureau of National Health Insurance (BNHI) and Director General of Center of Disease Control. Dr. Chang received his medical degree from National Yang-Ming Medical College. He also holds Masters degree in Public Health from National Taiwan University, and Master of Science in Health Policy and Management from Harvard School of Public Health.
Dr. Jo Shen is the Co-Founder for ScinoPharm Taiwan, Ltd., and served as its Chief Executive Officer and President for 17 years. Dr. Shen has more than 40 years of experience in the industry regarding international pharmaceutical executive. Prior to ScinoPharm, she worked with Syntex and Monsanto. Dr. Shen holds a Ph.D. in Physical Chemistry from Lehigh University, a M.S. in Inorganic Chemistry from the University of Iowa and a B.S. in Chemical Engineering from National Taiwan University. Dr. Shen is a Venture Partner at Vivo Capital, LLC since 2016.
Dr. Weng-Foung Huang is Adjunct Professor at Institute of Health and Welfare Policy at National Yang-Ming University. He also serves as Board Director at Taiwan Bio Industry Organization and Board Director at Development Center for Biotechnology. Dr. Huang was Chairman of Pharmacist Disciplinary Committee in Ministry of Health and Welfare and Director General of National Laboratories of Foods and Drugs in Department of Health of Taiwan.

Founded in 2020, CDIB Capital Healthcare Ventures II follows the Taiwan+ investment strategy, makes good use of the advantages of Taiwan’s talents and supporting facilities. Cooperate with Taiwanese and Chinese entrepreneurs or enterprises with successful business experience, connect domestic and foreign resources and business opportunities, and invest in biotechnology, medicine, medical technology, digital healthcare, other biomedical health and service-related industries.

HanTech Venture Capital is one of the oldest funds in Taiwan. It has been focusing on innovative technology and market development in Taiwan and Silicon Valley for a long time, fully grasping the industry development trend, the latest technology, and the application market to improve the accuracy of investment direction and investment performance. Till now, HanTech Venture Capital has invested in more than 200 companies.

Dr. Jen-Fang Lee obtained his Ph.D. degree in Buisness from National Chengchi University. He was Founding Director of FJCU Graduate Institute of Management Research , and Director/ Professor of NCCU Graduate Institute of Technology Management. He has served as a member of National Development Fund Venture Capital Review Committee, Convener of expert review meeting in industrial research and development master class of Ministry of Economic Affairs’ elite cultivation program, Director of Mega First Venture Capital Co., Director of Taiwan Design Center, Independent Director of Gigastone Corporation, and Deputy Director of the Council for Cultural Affairs, Executive Yuan. Professor Lee currently serves as Independent Director of BenQ Medical Technology Corporation and Rechi Precision Co., Ltd.
Dr. Yu-Hui Su currently serves as Distinguished Professor in the Department of Accounting of Soochow University. She obtained her Ph.D. degree from Business Administration, National Taiwan University and earned US Fulbright Visiting Scholar Award in 2000. Her professional credentials include Certified Public Accountant of ROC (CPA), International Internal Auditor (CIA), and Certification in Control Self-Assessment (CCSA). She used to be Supervisor of Chinese Petroleum Corporation, Mega Bank, Bank of Kaohsiung, Independent Director of TWi Pharmaceuticals, and Secretary-General of Taiwan Accounting Association.
Dr. Leah Lo got her Ph. D. degree from University of Massachusetts. Her scientific training background covers biochemistry and physical-chemical properties of protein and polysaccharides. She attended the Summer Institute at Franklin Pierce Law Center (now, University of New Hampshire) in order to obtain an extensive training in the area of intellectual property rights (IPR) and technology transfer. She also finished her business administration program from the Business School of National Chengchi University. Her passed full time job included serving as the President of Orient Pharma Inc.; President of Medical and Pharmaceutical Industry Technology and Development Center (PITDC); Director of Open Innovation Center, Ministry of Economic Affairs; Director of Technology Transfer Office, National Health Research Institutes (NHRI); Deputy Director of Science and Technology Law Center, Institute for Information Industry (III); Manager of Technology Transfer and International Affairs, Development Center for Biotechnology (DCB). She was the adjunct Professor at National Taiwan Ocean University. She also served as the Member of Intellectual Property Rights Committees among government affiliates, e.g. Council of Agriculture, National Science Council, Chinese National Federation of Industries etc.

Development Pipeline

Scroll to Top